| Filed On | Filing |
|---|---|
| 10 Nov 2026 |
8-K: Results of Operations and Financial Condition
– New Drug Application for Seralutinib in PAH Submitted to the U.S. FDA in September 2026 – |
| 10 Nov 2026 | 10-Q |
| 06 Nov 2026 | SCHEDULE 13G/A |
| 06 Nov 2026 | SCHEDULE 13G |
| 29 Oct 2026 | SCHEDULE 13D/A |
| 28 Oct 2026 |
8-K: Submission of Matters to a Vote of Security Holders
The following is a brief description of the matter voted upon at the special meeting of stockholders of Gossamer Bio, Inc. (the “Company”) held on October 27, 2026 (the “Special Meeting”) and the number of votes cast for or against, the ... |
| 08 Oct 2026 | SCHEDULE 13D/A |
| 28 Sep 2026 | SCHEDULE 13D/A |
| 28 Sep 2026 |
8-K: Other Events
On September 25, 2026, Gossamer Bio, Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company has regained compliance with the minimum bid price ... |
| 25 Sep 2026 |
Form 4: Milligan Sandra, Director
Granted 10,000 Stock Option (Right to Buy) |
| 25 Sep 2026 |
Form 4: Daniel Thomas O, Director
Granted 10,000 Stock Option (Right to Buy) |
| 25 Sep 2026 |
Form 4: Ciongoli Gregory Austin, Director
Granted 30,000 Stock Option (Right to Buy) |
| 25 Sep 2026 |
Form 4: Drynan Skye, Director
Granted 10,000 Stock Option (Right to Buy) |
| 25 Sep 2026 |
Form 4: Quisel John D, Director
Granted 10,000 Stock Option (Right to Buy) |
| 25 Sep 2026 |
Form 4: Cox Russell J., Director
Granted 10,000 Stock Option (Right to Buy) |
| 25 Sep 2026 |
Form 4: Nathan Steven D, Director
Granted 10,000 Stock Option (Right to Buy) |
| 23 Sep 2026 |
8-K: Other Events
On September 23, 2026, Gossamer Bio, Inc. (the “Company”) announced that it submitted a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) in September 2026 for seralutinib for the treatment of pulmonary arteri... |
| 22 Sep 2026 | Form 3: Ciongoli Gregory Austin, Director |
| 16 Sep 2026 | DEF 14A |
| 16 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
SAN DIEGO — (BUSINESS WIRE) — September 16, 2026 — Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hype... |
Loading...